Business Context and Reporting Period
Company: ORAGENICS INC
Filing Type: Form 8-K (Current Report)
Date of Report: January 9, 2007 (Earliest event reported)
Event Date: January 16, 2007 (Press release date referenced in filing)
Context: The filing reports the full exercise of remaining outstanding warrants issued during a December 2005 private financing.
Key Financial Metrics
- Proceeds from Warrant Exercise: $832,500
- Shares Issued: 1,387,500 shares of common stock
- Warrant Exercise Price: $0.60 per share
- Liquidity Impact: Immediate increase in cash reserves upon deposit of final amounts on January 9, 2007.
- Other Metrics: The filing text does not provide clear values for revenue, profit, operating margins, or total debt levels.
Material Changes
The primary material change is the acceleration and subsequent full exercise of the 2005 warrants. The company accelerated the expiration of these warrants to January 8, 2007, resulting in the issuance of 1,387,500 additional shares and the receipt of $832,500 in capital. This transaction was executed under the exemption from registration provided by Section 4(2) of the Securities Act of 1933.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the successful closure of the warrant exercise process initiated in December 2005. No forward-looking guidance or specific outlook statements are included in this 8-K text.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard disclosure of the unregistered sale of equity securities.
Investor Verification Checklist
- Verify the total number of outstanding shares post-issuance (1,387,500 new shares added).
- Confirm the cash balance impact of the $832,500 proceeds in the most recent 10-Q or 10-K.
- Review the attached Press Release (Exhibit 99.1) for any additional strategic context regarding the capital raise.
- Check for any dilution effects on existing shareholders resulting from the 1,387,500 new shares.